Funding for this research was provided by:
Horizon 2020 (754923)
Institut National de la Santé et de la Recherche Médicale
Ligue Contre le Cancer
Institut National Du Cancer
Université de Paris
Cancer Research for Personalized Medicine
FONCER contre le cancer
Labex Immuno-Oncology (LAXE62_9UMRS972)
Received: 30 March 2020
Accepted: 14 September 2020
First Online: 6 October 2020
Ethics approval and consent to participate
: The use of animals followed the institutional guidelines and the recommendations for the care and use of laboratory animals with approvals APAFIS#34\0-2016052518485390v2 and #9853-2017050211531651v5 by the French Ministry of Agriculture.
: Not applicable
: WHF is a consultant for Adaptimmune, AstraZeneca, Novartis, Anaveon, Catalym, Oxford Biotherapeutics, OSE immunotherapeutics, Zelluna, and IPSEN. The remaining authors declare that they have no competing interests.